May
29
Blog
Recent Posts
- JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Rituximab Biosimilar
- JHL Biotech Announces China Approves Phase I and Phase III Clinical Trial Application for Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma
- JHL Biotech Announces Completion of Convertible Bond Issuance and Appointment of New Chief Financial Officer
Comments are closed.